title: Decrease in beta 1- and increase in beta 2-adrenoceptors in long-term follow-up after orthotopic cardiac transplantation.
abstract: Total beta 1- and beta 2- subtype distribution were examined in right ventricular biopsies taken from 100 patients 1-60 months after orthotopic cardiac transplantation and from eight prospective transplant donor hearts serving as controls. The patients were classified into eight groups depending on the time after transplantation that the biopsies were taken: 1-3 (n = 15), 4-7 (n = 15), 8-11 (n = 6), 12 (n = 15), 24 (n = 15), 36 (n = 12), 48 (n = 12) and 60 months (n = 10). The non-selective beta-adrenoceptor antagonist (-)-[125I]-iodocyanopindolol (ICYP) was used as a radioligand to assess total beta-adrenoceptor density. The beta 1- and beta 2-subtype distribution was determined with a beta 1-adrenoceptor saturating concentration of the selective beta 1-adrenoceptor antagonist CGP 20712A (300 nmol/l). In transplant donor hearts the total beta-adrenoceptor density was found to be 70.8 +/- 7.1 fmol/mg protein including a beta 1:beta 2-adrenoceptor ratio of about 80:20%. Until 36 months after cardiac transplantation the total number of beta-adrenoceptors showed no significant change. A slight but insignificant decrease was observed after 48 (16.2%) and 60 (21.2%) months. In contrast, from 12 to 60 months after cardiac transplantation the beta 1:beta 2-adrenoceptor ratio was shifted significantly (66:33% to 61:39%) as compared with transplant donor hearts which was due to an increase in beta 2- and a decrease in beta 1-adrenoceptor number. Thus, the surgically denervated, transplanted human heart exhibits a beta 2-adrenoceptor up-regulation during long-term follow-up. It is suggested that this up-regulation of the beta 2-adrenoceptor subtype could be owing to an increased importance of circulating catecholamines in modulating positive chronotropic and inotropic effects.
authors.affiliation: Pharmakologisches Kerninstitut, Universitäts-Krankenhaus-Eppendorf, Universität Hamburg, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Steinfath
authors.forename: H
authors.initials: H
authors.lastname: von der Leyen
authors.forename: A
authors.initials: A
authors.lastname: Hecht
authors.forename: K H
authors.initials: KH
authors.lastname: Neumann
authors.forename: W
authors.initials: W
authors.lastname: Schmitz
authors.forename: H
authors.initials: H
authors.lastname: Scholz
authors.forename: A
authors.initials: A
authors.lastname: Haverich
authors.forename: B
authors.initials: B
authors.lastname: Heublein
mesh_terms: D000328:Adult; D001706:Biopsy; D006328:Cardiac Catheterization; D002311:Cardiomyopathy, Dilated / Q000601:surgery; D015536:Down-Regulation; D005260:Female; D005500:Follow-Up Studies; D016027:Heart Transplantation / Q000502:physiology; D006439:Hemodynamics; D006801:Humans; D020120:Iodocyanopindolol; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000473:pathology; D010869:Pindolol / Q000031:analogs & derivatives / Q000378:metabolism; D011943:Receptors, Adrenergic, beta / Q000032:analysis* / Q000378:metabolism
chemical_list: D011943:Receptors, Adrenergic, beta; D020120:Iodocyanopindolol; D010869:Pindolol